European-style health care reforms could weaken the war on cancer.

If the Food and Drug Administration's policy stands, cancer patients will have to wait many more years to get access to new drugs, and they will have fewer options in the process.

When it comes to making new drugs safer, most of the obvious solutions are already accounted for; we have reached the flat part of a curve that measures incremental safety against the additional cost.

There are good reasons for the European Union to worry about the health of its pharmaceutical firms, but fortunately there are things it can improve.

It is not in any industry"s interests to share information that will lead to costly regulations.So how do government regulators secure needed information from industry?

A fresh crop of caution inside the FDA may keep the agency out of the news, but it won't keep cancer patients from dying.

Congress seems increasingly intent on usurping the judgment of doctors. This will hit the poor especially hard.

Congress should act in protecting patents for follow-on biologics, relying on a few basic principles that do not suppress research and developmentin this vital sector.